Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Salloum FN
- Tocchetti CG
- Ameri P
- Ardehali H
- Asnani A
- de Boer RA
- Burridge P
- Cabrera JÁ
- de Castro J
- Córdoba R
- Dent S
- Engelbertsen D
- Fernández-Velasco M
- Fradley M
- Fuster JJ
- Galán-Arriola C
- García-Lunar I
- Ghigo A
- González-Neira A
- Hirsch E
- Ibáñez B
- Kitsis RN
- Konety S
- Lyon AR
- Martin P
- Mauro AG
- Mazo Vega MM
- Meijers WC
- Neilan TG
- Rassaf T
- Ricke-Hoch M
- Thavendiranathan P
- van der Meer P
- Fuster V
- Ky B
- López-Fernández T
- International Cardio-Oncology Society
Grupos
Abstract
Despite improvements in cancer survival, cancer therapy-related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning field of cardio-oncology, which aims to advance the cardiovascular health of cancer patients and survivors, through actionable and translatable science. In these Global Cardio-Oncology Symposium 2023 scientific symposium proceedings, we present a focused review on the mechanisms that contribute to common cardiovascular toxicities discussed at this meeting, the ongoing international collaborative efforts to improve patient outcomes, and the bidirectional challenges of translating basic research to clinical care. We acknowledge that there are many additional therapies that are of significance but were not topics of discussion at this symposium. We hope that through this symposium-based review we can highlight the knowledge gaps and clinical priorities to inform the design of future studies that aim to prevent and mitigate cardiovascular disease in cancer patients and survivors.
© 2023 The Authors.
Datos de la publicación
- ISSN/ISSNe:
- 2666-0873, 2666-0873
- Tipo:
- Article
- Páginas:
- 715-731
- PubMed:
- 38205010
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 1,687 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JACC: CardioOncology ELSEVIER
Citas Recibidas en Web of Science: 42
Citas Recibidas en Scopus: 34
Documentos
- No hay documentos
Filiaciones
Keywords
- anthracyclines; basic research; cancer; cardiac arrhythmias; cardio-oncology; cardiotoxicity; chemotherapy; immunotherapy; targeted therapies; translational research
Campos de Estudio
Cita
Salloum FN,Tocchetti CG,Ameri P,Ardehali H,Asnani A,de Boer RA,Burridge P,Cabrera JÁ,de Castro J,Córdoba R,COSTA A,Dent S,Engelbertsen D,Fernández M,Fradley M,Fuster JJ,Galán C,García I,Ghigo A,González A,Hirsch E,Ibáñez B,Kitsis RN,Konety S,Lyon AR,Martin P,Mauro AG,Mazo MM,Meijers WC,Neilan TG,Rassaf T,Ricke M,SEPULVEDA P,Thavendiranathan P,van der Meer P,Fuster V,KYB,López T,International Cardio S. Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review. JACC-Cardiooncol. 2023. 5. (6):p. 715-731. IF:13,600. (1).
Portal de investigación